Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine.

Autor: Arunachalam PS; Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA., Feng Y; Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA., Ashraf U; Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA., Hu M; Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA., Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA., Edara VV; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, and Emory University School of Medicine, Atlanta, GA 30329, USA., Zarnitsyna VI; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30329, USA., Aye PP; Tulane National Primate Research Center, Covington, LA 70433, USA., Golden N; Tulane National Primate Research Center, Covington, LA 70433, USA., Miranda MC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Green KWM; Tulane National Primate Research Center, Covington, LA 70433, USA., Threeton BM; Tulane National Primate Research Center, Covington, LA 70433, USA., Maness NJ; Tulane National Primate Research Center, Covington, LA 70433, USA., Beddingfield BJ; Tulane National Primate Research Center, Covington, LA 70433, USA., Bohm RP; Tulane National Primate Research Center, Covington, LA 70433, USA., Scheuermann SE; Tulane National Primate Research Center, Covington, LA 70433, USA., Goff K; Tulane National Primate Research Center, Covington, LA 70433, USA., Dufour J; Tulane National Primate Research Center, Covington, LA 70433, USA., Russell-Lodrigue K; Tulane National Primate Research Center, Covington, LA 70433, USA., Kepl E; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Fiala B; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Wrenn S; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Ravichandran R; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Ellis D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Carter L; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Rogers K; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA., Shirreff LM; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA., Ferrell DE; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA., Deb Adhikary NR; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA., Fontenot J; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA., Hammond HL; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Frieman M; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Grifoni A; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA., Sette A; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA., O'Hagan DT; GSK, Rockville, MD 20850, USA., Van Der Most R; GSK, Rixensart 1330, Belgium., Rappuoli R; GSK, Siena 53100, Italy., Villinger F; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA 70560, USA., Kleanthous H; Bill and Melinda Gates Foundation, Seattle, WA 98109, USA., Rappaport J; Tulane National Primate Research Center, Covington, LA 70433, USA.; Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA 70112, USA., Suthar MS; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, and Emory University School of Medicine, Atlanta, GA 30329, USA., Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA., Wang TT; Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA.; Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA 94305, USA., King NP; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Institute for Protein Design, University of Washington, Seattle, WA 98195, USA., Pulendran B; Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA.; Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA 94305, USA.; Department of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Jazyk: angličtina
Zdroj: Science translational medicine [Sci Transl Med] 2022 Aug 17; Vol. 14 (658), pp. eabq4130. Date of Electronic Publication: 2022 Aug 17.
DOI: 10.1126/scitranslmed.abq4130
Abstrakt: Despite the remarkable efficacy of COVID-19 vaccines, waning immunity and the emergence of SARS-CoV-2 variants such as Omicron represents a global health challenge. Here, we present data from a study in nonhuman primates demonstrating durable protection against the Omicron BA.1 variant induced by a subunit SARS-CoV-2 vaccine comprising the receptor binding domain of the ancestral strain (RBD-Wu) on the I53-50 nanoparticle adjuvanted with AS03, which was recently authorized for use in individuals 18 years or older. Vaccination induced neutralizing antibody (nAb) titers that were maintained at high concentrations for at least 1 year after two doses, with a pseudovirus nAb geometric mean titer (GMT) of 1978 and a live virus nAb GMT of 1331 against the ancestral strain but not against the Omicron BA.1 variant. However, a booster dose at 6 to 12 months with RBD-Wu or RBD-β (RBD from the Beta variant) displayed on I53-50 elicited high neutralizing titers against the ancestral and Omicron variants. In addition, we observed persistent neutralization titers against a panel of sarbecoviruses, including SARS-CoV. Furthermore, there were substantial and persistent memory T and B cell responses reactive to Beta and Omicron variants. Vaccination resulted in protection against Omicron infection in the lung and suppression of viral burden in the nares at 6 weeks after the final booster immunization. Even at 6 months after vaccination, we observed protection in the lung and rapid control of virus in the nares. These results highlight the durable and cross-protective immunity elicited by the AS03-adjuvanted RBD-I53-50 nanoparticle vaccine.
Databáze: MEDLINE